Oligoastrocytomas belong to a group of brain tumors called “gliomas.” Gliomas are tumors that come from the glial, or supportive, cells of the brain. There are several different types of gliomas. An oligoastrocytoma is a “mixed glioma” tumor, which contains both abnormal oligodendroglioma and astrocytoma cells. Oligoastrocytomas (grade II) are considered low-grade tumors. They generally grow at a slower rate than anaplastic oligoastrocytomas (grade III), which are malignant. Oligoastrocytomas may evolve over time into anaplastic oligoastrocytomas.


These tumors can be found anywhere within the cerebral hemispheres of the brain, although the frontal and temporal lobes are the most common locations.


The most common symptoms of oligoastrocytoma are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor.


If the tumor is accessible, standard treatment for oligoastrocytoma is surgical removal of as much of the tumor tissue as possible. Biopsy is typically performed on tumors that are not accessible to confirm the diagnosis and determine the grade of tumor.

Your doctor may talk with you about chemotherapy as part of the treatment plan. Chemotherapy may also be used in infants and very young children to delay radiation therapy until the patient is older.


About 40% of primary brain tumors are gliomas. Mixed gliomas, primarily oligoastrocytomas, account for 5-10% of gliomas and 1% of all brain tumors. Oligoastrocytomas develop in young and middle-aged adults (ages 30 to 50). Very few children are diagnosed with oligoastrocytoma.

Close Menu
en English

Mindee Plugues


Mindee J. Plugues, of Los Angeles, CA, is vice president, marketing for the Applebee’s brand and brings skills including brand strategy, executive leadership, and marketing to the board. Plugues has been an ABTA donor since April 2001, following her father’s passing from GBM. She is also a former member of the ABTA endurance program, Team Breakthrough.

Bob Kruchten


Bob Kruchten, of Mount Prospect, IL, is a sales manager at Extreme Reach, a leading advertising technology company. He has strong skills in communications and fundraising, and has been advocating for the ABTA for 19 years in tribute to his best friend, Paul Fabbri, who lost his 10-year battle with GBM in 1998. Kruchten accepted the ABTA’s Joel A. Gingras Jr. Award in 2015 on behalf of the Paul Fabbri Memorial Fund.